New drug AZD0780 aims to lower blood pressure in heart patients
NCT ID NCT06692764
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called AZD0780 in 202 people with heart disease or related risks and high LDL cholesterol. Participants took either the drug or a placebo for 4 weeks, and researchers measured changes in blood pressure using a 24-hour monitor. The goal was to see if AZD0780 can safely lower blood pressure in this high-risk group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AZD0780
What this could lead to
If successful, AZD0780 could offer a new way to lower blood pressure in people with heart disease and high cholesterol, potentially reducing heart attack and stroke risk.
What could go wrong
This is a small, early Phase II study with only 202 participants. Results may not apply to everyone, and the drug may not prove effective or safe in larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Inglewood, California, 90301, United States
-
Research Site
Northridge, California, 91325, United States
-
Research Site
Pomona, California, 91767, United States
-
Research Site
Boca Raton, Florida, 33434, United States
-
Research Site
Hialeah, Florida, 33012, United States
-
Research Site
Jacksonville, Florida, 32216, United States
-
Research Site
Miami, Florida, 33122, United States
-
Research Site
Miami, Florida, 33165, United States
-
Research Site
Miami, Florida, 33173, United States
-
Research Site
Miami, Florida, 33174, United States
-
Research Site
Ocala, Florida, 34474, United States
-
Research Site
Port Orange, Florida, 32127, United States
-
Research Site
Tamarac, Florida, 33321, United States
-
Research Site
Chicago, Illinois, 60621, United States
-
Research Site
Potomac, Maryland, 20854, United States
-
Research Site
New Bedford, Massachusetts, 02740, United States
-
Research Site
New Windsor, New York, 12553, United States
-
Research Site
Beavercreek, Ohio, 45431, United States
-
Research Site
Horsham, Pennsylvania, 19044, United States
-
Research Site
Spartanburg, South Carolina, 29303, United States
-
Research Site
Austin, Texas, 78704, United States
-
Research Site
Dallas, Texas, 75230, United States
-
Research Site
El Paso, Texas, 79905, United States
-
Research Site
Hurst, Texas, 76054, United States
-
Research Site
Mesquite, Texas, 75149, United States
-
Research Site
Paris, Texas, 75462, United States